Supplies electronic ambulatory infusion pumps. Provides disposable supply kits for infusion pumps. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
This is an established company with proven profits.
Average growth of 9% a year over the last 4 years. Every year shown ended in profit.
The market pays 37× for every dollar this company earns in a year — a price that already assumes things go well.
Against companies in its own sector, it looks cheaper than 75% of them.
Analysts' average target sits 23% above today's price.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.
Clearly above the class average — a step short of the very top.
Sales are growing strongly for its sector.
The stock has been running stronger than the market lately.
No real weak spot in any of the five subjects — a balanced report card.
The stock trades 34% below its peak. The market has trimmed its expectations for the company.
Over the last 4 years, sales grew about 9% a year on average.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
Over the last 12 months, company executives reported 31 buys and 21 sells. Management buying with its own money is usually read as a good sign.
The company’s market value is 37 times its annual profit. Even a small disappointment could hit the price hard.
Costs swallow the gains that sales growth brings in.
On our five-subject report card, INFU sits near the top of the class. A high grade doesn’t mean “guaranteed win” — it means “the evidence looks strong for now.”
The takeaway: INFU is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.